Biomarin Pharmaceutical Stock Volatility
| BMRN Stock | USD 92.06 2.57 2.87% |
We consider Biomarin Pharmaceutical very steady. Biomarin Pharmaceutical secures Sharpe Ratio (or Efficiency) of 0.0176, which signifies that the company had a 0.0176% return per unit of risk over the last 3 months. We have found twenty-two technical indicators for Biomarin Pharmaceutical, which you can use to evaluate the volatility of the firm. Please confirm Biomarin Pharmaceutical's Risk Adjusted Performance of (0.02), standard deviation of 1.2, and Mean Deviation of 0.9487 to double-check if the risk estimate we provide is consistent with the expected return of 0.0219%. Key indicators related to Biomarin Pharmaceutical's volatility include:
30 Days Market Risk | Chance Of Distress | 30 Days Economic Sensitivity |
Biomarin Pharmaceutical Stock volatility depicts how high the prices fluctuate around the mean (or its average) price. In other words, it is a statistical measure of the distribution of Biomarin daily returns, and it is calculated using variance and standard deviation. We also use Biomarin's beta, its sensitivity to the market, as well as its odds of financial distress to provide a more practical estimation of Biomarin Pharmaceutical volatility.
Biomarin |
ESG Sustainability
While most ESG disclosures are voluntary, Biomarin Pharmaceutical's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Biomarin Pharmaceutical's managers and investors.Environment Score | Governance Score | Social Score |
Since volatility provides investors with entry points to take advantage of stock prices, companies, such as Biomarin Pharmaceutical can benefit from it. Downward market volatility can be a perfect environment for investors who play the long game. Here, they may decide to buy additional stocks of Biomarin Pharmaceutical at lower prices. For example, an investor can purchase Biomarin stock that has halved in price over a short period. This will lower your average cost per share, thereby improving your portfolio's performance when the markets normalize. Similarly, when the prices of Biomarin Pharmaceutical's stock rises, investors can sell out and invest the proceeds in other equities with better opportunities. Investing when markets are volatile with better valuations will accord both investors and companies the opportunity to generate better long-term returns.
Moving against Biomarin Stock
| 0.72 | PBH | Prestige Brand Holdings Financial Report 2nd of May 2024 | PairCorr |
| 0.62 | SUPN | Supernus Pharmaceuticals Financial Report 14th of May 2024 | PairCorr |
| 0.59 | RDY | Dr Reddys Laboratories Financial Report 8th of May 2024 | PairCorr |
| 0.59 | KROS | Keros TherapeuticsInc Financial Report 2nd of May 2024 | PairCorr |
| 0.58 | MRUS | Merus BV Financial Report 2nd of May 2024 | PairCorr |
| 0.52 | HLVX | Hillevax Financial Report 10th of May 2024 | PairCorr |
| 0.52 | SNDX | Syndax Pharmaceuticals Financial Report 13th of May 2024 | PairCorr |
| 0.51 | ANIP | ANI Pharmaceuticals Financial Report 13th of May 2024 | PairCorr |
| 0.46 | AVTE | Aerovate Therapeutics Financial Report 20th of May 2024 | PairCorr |
Biomarin Pharmaceutical Market Sensitivity And Downside Risk
Biomarin Pharmaceutical's beta coefficient measures the volatility of Biomarin stock compared to the systematic risk of the entire market represented by your selected benchmark. In mathematical terms, beta represents the slope of the line through a regression of data points where each of these points represents Biomarin stock's returns against your selected market. In other words, Biomarin Pharmaceutical's beta of 0.48 provides an investor with an approximation of how much risk Biomarin Pharmaceutical stock can potentially add to one of your existing portfolios. Biomarin Pharmaceutical exhibits very low volatility with skewness of 0.03 and kurtosis of -0.37. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Biomarin Pharmaceutical's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Biomarin Pharmaceutical's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.
3 Months Beta |Analyze Biomarin Pharmaceutical Demand TrendCheck current 90 days Biomarin Pharmaceutical correlation with market (NYSE Composite)Biomarin Beta |
Biomarin standard deviation measures the daily dispersion of prices over your selected time horizon relative to its mean. A typical volatile entity has a high standard deviation, while the deviation of a stable instrument is usually low. As a downside, the standard deviation calculates all uncertainty as risk, even when it is in your favor, such as above-average returns.
Standard Deviation | 1.25 |
It is essential to understand the difference between upside risk (as represented by Biomarin Pharmaceutical's standard deviation) and the downside risk, which can be measured by semi-deviation or downside deviation of Biomarin Pharmaceutical's daily returns or price. Since the actual investment returns on holding a position in biomarin stock tend to have a non-normal distribution, there will be different probabilities for losses than for gains. The likelihood of losses is reflected in the downside risk of an investment in Biomarin Pharmaceutical.
Using Biomarin Put Option to Manage Risk
Put options written on Biomarin Pharmaceutical grant holders of the option the right to sell a specified amount of Biomarin Pharmaceutical at a specified price within a specified time frame. The put buyer has a limited loss and, while not fully unlimited gains, as the price of Biomarin Stock cannot fall below zero, the put buyer does gain as the price drops. So, one way investors can hedge Biomarin Pharmaceutical's position is by buying a put option against it. The put option used this way is usually referred to as insurance. If an undesired outcome occurs and loss on holding Biomarin Pharmaceutical will be realized, the loss incurred will be offset by the profits made with the option trade.
Biomarin Pharmaceutical's PUT expiring on 2024-05-17
Profit |
| Biomarin Pharmaceutical Price At Expiration |
Current Biomarin Pharmaceutical Insurance Chain
| Delta | Gamma | Open Int | Expiration | Current Spread | Last Price | |||
Put | 2024-05-17 PUT at $100.0 | -0.8525 | 0.0259 | 10 | 2024-05-17 | 9.7 - 12.3 | 9.93 | View |
Put | 2024-05-17 PUT at $95.0 | -0.6948 | 0.0383 | 30 | 2024-05-17 | 6.6 - 7.3 | 7.0 | View |
Put | 2024-05-17 PUT at $90.0 | -0.4916 | 0.0436 | 1159 | 2024-05-17 | 3.6 - 4.1 | 3.8 | View |
Put | 2024-05-17 PUT at $85.0 | -0.276 | 0.0375 | 2213 | 2024-05-17 | 1.1 - 1.9 | 1.6 | View |
Put | 2024-05-17 PUT at $80.0 | -0.102 | 0.0211 | 347 | 2024-05-17 | 0.15 - 0.7 | 0.5 | View |
Biomarin Pharmaceutical Stock Volatility Analysis
Volatility refers to the frequency at which Biomarin Pharmaceutical stock price increases or decreases within a specified period. These fluctuations usually indicate the level of risk that's associated with Biomarin Pharmaceutical's price changes. Investors will then calculate the volatility of Biomarin Pharmaceutical's stock to predict their future moves. A stock that has erratic price changes quickly hits new highs, and lows are considered highly volatile. A stock with relatively stable price changes has low volatility. A highly volatile stock is riskier, but the risk cuts both ways. Investing in highly volatile security can either be highly successful, or you may experience significant failure. There are two main types of Biomarin Pharmaceutical's volatility:
Historical Volatility
This type of stock volatility measures Biomarin Pharmaceutical's fluctuations based on previous trends. It's commonly used to predict Biomarin Pharmaceutical's future behavior based on its past. However, it cannot conclusively determine the future direction of the stock.Implied Volatility
This type of volatility provides a positive outlook on future price fluctuations for Biomarin Pharmaceutical's current market price. This means that the stock will return to its initially predicted market price. This type of volatility can be derived from derivative instruments written on Biomarin Pharmaceutical's to be redeemed at a future date.Transformation |
The output start index for this execution was zero with a total number of output elements of sixty-one. Biomarin Pharmaceutical Average Price is the average of the sum of open, high, low and close daily prices of a bar. It can be used to smooth an indicator that normally takes just the closing price as input.
Biomarin Pharmaceutical Projected Return Density Against Market
Given the investment horizon of 90 days Biomarin Pharmaceutical has a beta of 0.4834 suggesting as returns on the market go up, Biomarin Pharmaceutical average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Biomarin Pharmaceutical will be expected to be much smaller as well.Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Biomarin Pharmaceutical or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Biomarin Pharmaceutical's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Biomarin stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
Biomarin Pharmaceutical has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the NYSE Composite. Predicted Return Density |
| Returns |
What Drives a Biomarin Pharmaceutical Price Volatility?
Several factors can influence a stock's market volatility:Industry
Specific events can influence volatility within a particular industry. For instance, a significant weather upheaval in a crucial oil-production site may cause oil prices to increase in the oil sector. The direct result will be the rise in the stock price of oil distribution companies. Similarly, any government regulation in a specific industry could negatively influence stock prices due to increased regulations on compliance that may impact the company's future earnings and growth.Political and Economic environment
When governments make significant decisions regarding trade agreements, policies, and legislation regarding specific industries, they will influence stock prices. Everything from speeches to elections may influence investors, who can directly influence the stock prices in any particular industry. The prevailing economic situation also plays a significant role in stock prices. When the economy is doing well, investors will have a positive reaction and hence, better stock prices and vice versa.The Company's Performance
Sometimes volatility will only affect an individual company. For example, a revolutionary product launch or strong earnings report may attract many investors to purchase the company. This positive attention will raise the company's stock price. In contrast, product recalls and data breaches may negatively influence a company's stock prices.Biomarin Pharmaceutical Stock Risk Measures
Given the investment horizon of 90 days the coefficient of variation of Biomarin Pharmaceutical is 5691.83. The daily returns are distributed with a variance of 1.55 and standard deviation of 1.25. The mean deviation of Biomarin Pharmaceutical is currently at 0.98. For similar time horizon, the selected benchmark (NYSE Composite) has volatility of 0.62
α | Alpha over NYSE Composite | -0.09 | |
β | Beta against NYSE Composite | 0.48 | |
σ | Overall volatility | 1.25 | |
Ir | Information ratio | -0.11 |
Biomarin Pharmaceutical Stock Return Volatility
Biomarin Pharmaceutical historical daily return volatility represents how much of Biomarin Pharmaceutical stock's daily returns swing around its mean - it is a statistical measure of its dispersion of returns. The firm inherits 1.2469% risk (volatility on return distribution) over the 90 days horizon. By contrast, NYSE Composite accepts 0.6371% volatility on return distribution over the 90 days horizon. Performance |
| Timeline |
About Biomarin Pharmaceutical Volatility
Volatility is a rate at which the price of Biomarin Pharmaceutical or any other equity instrument increases or decreases for a given set of returns. It is measured by calculating the standard deviation of the annualized returns over a given period of time and shows the range to which the price of Biomarin Pharmaceutical may increase or decrease. In other words, similar to Biomarin's beta indicator, it measures the risk of Biomarin Pharmaceutical and helps estimate the fluctuations that may happen in a short period of time. So if prices of Biomarin Pharmaceutical fluctuate rapidly in a short time span, it is termed to have high volatility, and if it swings slowly in a more extended period, it is understood to have low volatility.
Please read more on our technical analysis page.| Last Reported | Projected for Next Year | ||
| Selling And Marketing Expenses | 488.4 M | 480.5 M | |
| Market Cap | 14.5 B | 8 B |
Biomarin Pharmaceutical's stock volatility refers to the amount of uncertainty or risk involved with the size of changes in its stock's price. It is a statistical measure of the dispersion of returns on Biomarin Stock over a specified period of time, often expressed as the standard deviation of daily returns. In other words, it measures how much Biomarin Pharmaceutical's price varies over time.
3 ways to utilize Biomarin Pharmaceutical's volatility to invest better
Higher Biomarin Pharmaceutical's stock volatility means that the price of its stock is changing rapidly and unpredictably, while lower stock volatility indicates that the price of Biomarin Pharmaceutical stock is relatively stable. Investors and traders use stock volatility as an indicator of risk and potential reward, as stocks with higher volatility can offer the potential for more significant returns but also come with a greater risk of losses. Biomarin Pharmaceutical stock volatility can provide helpful information for making investment decisions in the following ways:- Measuring Risk: Volatility can be used as a measure of risk, which can help you determine the potential fluctuations in the value of Biomarin Pharmaceutical investment. A higher volatility means higher risk and potentially larger changes in value.
- Identifying Opportunities: High volatility in Biomarin Pharmaceutical's stock can indicate that there is potential for significant price movements, either up or down, which could present investment opportunities.
- Diversification: Understanding how the volatility of Biomarin Pharmaceutical's stock relates to your other investments can help you create a well-diversified portfolio of assets with varying levels of risk.
Biomarin Pharmaceutical Investment Opportunity
Biomarin Pharmaceutical has a volatility of 1.25 and is 1.95 times more volatile than NYSE Composite. 11 percent of all equities and portfolios are less risky than Biomarin Pharmaceutical. You can use Biomarin Pharmaceutical to enhance the returns of your portfolios. The stock experiences an unexpected upward trend. Watch out for market signals. Check odds of Biomarin Pharmaceutical to be traded at $110.47 in 90 days.Modest diversification
The correlation between Biomarin Pharmaceutical and NYA is 0.25 (i.e., Modest diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Biomarin Pharmaceutical and NYA in the same portfolio, assuming nothing else is changed.
Biomarin Pharmaceutical Additional Risk Indicators
The analysis of Biomarin Pharmaceutical's secondary risk indicators is one of the essential steps in making a buy or sell decision. The process involves identifying the amount of risk involved in Biomarin Pharmaceutical's investment and either accepting that risk or mitigating it. Along with some common measures of Biomarin Pharmaceutical stock's risk such as standard deviation, beta, or value at risk, we also provide a set of secondary indicators that can assist in the individual investment decision or help in hedging the risk of your existing portfolios.
| Risk Adjusted Performance | (0.02) | |||
| Market Risk Adjusted Performance | (0.10) | |||
| Mean Deviation | 0.9487 | |||
| Coefficient Of Variation | (2,754) | |||
| Standard Deviation | 1.2 | |||
| Variance | 1.44 | |||
| Information Ratio | (0.11) |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential stocks, we recommend comparing similar stocks with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Biomarin Pharmaceutical Suggested Diversification Pairs
Pair trading is one of the very effective strategies used by professional day traders and hedge funds capitalizing on short-time and mid-term market inefficiencies. The approach is based on the fact that the ratio of prices of two correlating shares is long-term stable and oscillates around the average value. If the correlation ratio comes outside the common area, you can speculate with a high success rate that the ratio will return to the mean value and collect a profit.
The effect of pair diversification on risk is to reduce it, but we should note this doesn't apply to all risk types. When we trade pairs against Biomarin Pharmaceutical as a counterpart, there is always some inherent risk that will never be diversified away no matter what. This volatility limits the effect of tactical diversification using pair trading. Biomarin Pharmaceutical's systematic risk is the inherent uncertainty of the entire market, and therefore cannot be mitigated even by pair-trading it against the equity that is not highly correlated to it. On the other hand, Biomarin Pharmaceutical's unsystematic risk describes the types of risk that we can protect against, at least to some degree, by selecting a matching pair that is not perfectly correlated to Biomarin Pharmaceutical.
When determining whether Biomarin Pharmaceutical offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biomarin Pharmaceutical's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biomarin Pharmaceutical Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biomarin Pharmaceutical Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biomarin Pharmaceutical. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Complementary Tools for Biomarin Stock analysis
When running Biomarin Pharmaceutical's price analysis, check to measure Biomarin Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biomarin Pharmaceutical is operating at the current time. Most of Biomarin Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Biomarin Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biomarin Pharmaceutical's price. Additionally, you may evaluate how the addition of Biomarin Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Bonds Directory Find actively traded corporate debentures issued by US companies |
Is Biomarin Pharmaceutical's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biomarin Pharmaceutical. If investors know Biomarin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biomarin Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.98 | Earnings Share 0.87 | Revenue Per Share 12.88 | Quarterly Revenue Growth 0.202 | Return On Assets 0.0163 |
The market value of Biomarin Pharmaceutical is measured differently than its book value, which is the value of Biomarin that is recorded on the company's balance sheet. Investors also form their own opinion of Biomarin Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Biomarin Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biomarin Pharmaceutical's market value can be influenced by many factors that don't directly affect Biomarin Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biomarin Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biomarin Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biomarin Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.